Promising cure to URTI pandemics, including the Avian flu - Part 2

[Guest guest]

http://www.findarticles.com/p/articles/mi_m0ISW/is_273/ai_n16118925

 

 

 

 

Promising cure to URTI pandemics, including the Avian flu - Part 2

 

 

Promising cure to URTI pandemics, including the Avian flu : has the

final solution to the coming plagues been discovered?

Townsend Letter for Doctors and Patients, April, 2006 by Eric

Gordon, Kent Holtorf

 

 

 

Continued

 

Electrargol was a 400 ppm concentration of silver in water equivalent

to 400 mcg/cc. (133,134) " The dose is 80 to 160 drops (5-10 cc),

injected intramuscularly or directly into a vein. " (135) This dose was

given several times weekly when indicated. (136,137) Therefore, the

typical single IV dosage totaled 2 mg to 4 mg silver as silver hydrosol.

 

So, what would be the modern dose equivalents when treating for acute

local or systemic infections for a picoscalar silver hydrosol

containing a pure oligodynamic content of 20 ppm to 25 ppm? Answer: IV

dosages given once or several times weekly for an average 70 kilo

patient, as either a 50 cc to 75 cc slow push or 150 cc to 200 cc

isotonic drip, as indicated. When exceeding 150 cc in a single IV

drip, it is important to diligently monitor for hemolysis with urine

dip sticks. Limit dosage on subsequent treatments to 150 cc if

significant hemolysis warrants. Insignificant levels of hemolysis need

not alter dosage levels.

 

For chronic infections with heavy loads and co-infections, what are

the in vivo guidelines for utilizing IV oligodynamic silver hydrosol

in humans? Research conducted at Lucha Contra el Sida, Comayaguela

hospital (discussed above) appears to have determined this guideline,

as well as the other end of the TI for oligodynamic silver. The

study's conclusion found that the equivalent (138) of 27 ppm

oligodynamic silver (as the target saturation point for the blood

plasma) was sufficient to completely convert to seronegative all

advanced AIDS patients presenting with frank candidiasis, when

provided as a single treatment dose! (139) To approach a 27 ppm blood

plasma concentration with a 20 ppm to 25 ppm oligodynamic silver

hydrosol formulation, see the following section on Protocol Proposal.

 

 

Protocol Proposal & Call for Clinical Investigators

 

In cases of acute URTIs, per os, nebulized, and intravenous

administration may prove to be the best infectious control method yet

discovered. What follows is a call for clinical investigators to

discover its fullest potential.

 

Per os dosage ranges are from one teaspoon to one tablespoon taken on

an empty stomach every 20 to 60 minutes during initial stages (first

week) of acute URTI, reducing dosages accordingly with symptom

alleviation. If symptoms do not show clear improvement within 24 to 36

hours, or if symptoms should worsen, then in addition to continuing

the upper p.o. dosage schedule, incorporating investigational

nebulized dosages of 5 cc given once or twice daily or even hourly may

be required. Follow up immediately with standard respiratory therapy,

when indicated. Reduce dosage amount and frequency accordingly as

symptoms improve. (Also, see below the section on jurisprudence.)

 

In severe cases that are stable or slowly deteriorating (acute

respiratory distress), or in cases where rapid improvement is deemed

medically necessary, investigational use of slow IV push given over 15

minutes of 50 cc to 75 cc once daily may bring about a rapid recovery

within the following 24 to 36 hours. IV push contents should be

prepared by a compounding pharmacy or an equivalent in-clinic

" clean-field " processing system that meets applicable state

regulations. By rendering the silver hydrosol suspension isotonic with

sorbitol, doses above 50 cc may be frequently given safely and

comfortably. 75 cc of isotonic silver hydrosol may be administered

daily as a slow push over three consecutive days, if the case

warrants. Reduce dosage amount and frequency accordingly as symptoms

improve.

 

In acute, critical cases with rapid deterioration (severe respiratory

distress), investigational use of isotonic IV drips administered to

attain a cumulative 1 ppm to 10 ppm oligodynamic silver blood plasma

concentration from all sources (p.o., nebulizer, and intravenous)

should bring about a swift efficacious response. To bring under

control a rapidly deteriorating case, providing an IV drip over three

hours of 150 cc isotonic silver hydrosol may be given daily for three

or more consecutive days, in conjunction with p.o. and nebulizer

treatments. Close monitoring for uneventful hepatomegaly or hemolysis

is required. Run a liver panel and/or a complete CBC if symptoms

indicate. Otherwise, simple monitoring for hemolysis via urine dip

sticks should suffice. If non-significant hemolysis or hepatomegaly

develops, dosage schedule may continue at the higher levels. In the

rare event that significant hemolysis or hepatomegaly arises, if

possible discontinue dosage for 24 to 72 hours, except for nebulized

administration, then resume dosage schedule as indicated above. Reduce

dosage amount and frequency accordingly as symptoms improve.

 

In chronic non-URTI viral cases involving heavy pathogen loads, with

or without significant URTI co-infections such as bacterial pneumonia

or fungal pneumocystis carinii or even tuberculosis, administering a

cycle of 150 cc to 200 cc isotonic silver hydrosol as an IV drip over

three hours daily for four consecutive days, followed by a rest period

of three days, can be repeated (when deemed necessary) for a total of

three more cycles (16 isotonic silver hydrosol drips in all over 30

days). P.o. dosages should be six tablespoons daily, only taken on an

empty stomach. Nebulized dosages remain the same as described above.

Advertisement

 

To further approach the " equivalent " of the 27 ppm silver

concentration mark in plasma, administer 125 cc of 0.0375% H202 over

60 minutes, one hour after completion of each 150 cc to 200 cc

isotonic silver hydrosol drip. Doing so may recharge inactive silver

back into oligodynamic silver and thereby greatly extend the

therapeusis of the silver without adding in additional quantities of

silver hydrosol. (See Gallyas F, and Feng QL, et al., references.) If

non-significant hemolysis or hepatomegaly develops, dosage schedule

may continue at the higher levels. As RNA copies/ml plummet and

symptoms improve, reduce dosages accordingly.

 

All dosages are for an average 70 to 75+ kilo adult patient, with per

os, investigational nebulized, or investigational IV dosages being cut

by one-half for patients approximately 37 kilos in size. For toddlers

less than 20 kilos, the dosages are further reduced to just

one-quarter of the adult amounts.

 

JHE Pre- And Post-Management

 

Pre-JHE Management: Prevention or lessening of expected JHEs or

hepatomegaly and hemolysis is a new concept. By giving the

antioxidants selenium, glutathione + anthocyanins, vitamin E, lipoic

acid, milk thistle (silymarin), and phosphatidylcholine in " loading "

doses, a rapid upregulation of the seleno-enzyme glutathione

peroxidase system will ensue. Tolerance to silver may go up by several

orders of magnitude with such loading doses. (140) The key either is

to take such loading doses a month or two prior to undergoing high

amounts of IV treatment or, at the very least, take these loading

dosages daily, but always separated by a six-hour period post-IV

administration. If taken together, each will tend to cancel out the

other's benefits by binding to one another, as opposed to their

intended targets.

 

Post-JHE Management: To rapidly control and eliminate post-JHE

symptoms, drinking an abundance of purified water (up to one quart

t.i.d.), along with including one cup strong organic coffee or

double-strength green tea rectal implants, should bring about

instantaneous results. (141) Retain the rectal implant for 20 minutes

or longer. Performing a purified water enema prior to the rectal

implant will better insure retention compliance and best results. In

rarer situations, careful screening for immune system activation of

coagulation (ISAC) (142) must be treated with heparin and/or

lumbokinase or nattokinase.

Advertisement

 

CAM Adjunctive Support

 

In addition to the recharging effects of administering

[H.sub.2][O.sub.2] post-IV silver hydrosol, garlic capsules rich in

Alliin, as opposed to Allicin, such as Pharmax's Garlic Freeze-Dried,

(143-146) and probiotics, such as Pharmax's HLC Intensive Capsules

containing over 20 billion viable organisms per capsule, (147) prove

very important in the management of URTIs, as well as any associated

gut dysbiosis.

 

Olive leaf extract rich in d-lenolate (148-151) can serve as an

excellent means to more slowly reduce viral loads. When given one to

two months in advance of IV silver hydrosol administration, this

ability of d-lenolate also will serve indirectly as an " adaptogen, "

wherein low-levels of die-off will induce tolerance for more

significant die-offs expected in the near future from silver

administration.

 

Jurisprudence

 

Four steps are required for proper jurisprudence concerning silver

hydrosol administration when used off-label: (1) A well written

Informed Consent form should be read and signed by any patients

undergoing nebulized or IV silver hydrosol treatment. (2) Clinical

progress notes must be complete and thorough. (3) Careful regular

monitoring with urine dip sticks for hemolysis and, if warranted,

follow-up CBC counts and liver panel screens may be advisable. (4)

Utilizing a compounding pharmacy or " in-clinic equivalent " according

to all state regulations when processing silver hydrosol off-label

into an injectible format is required.

 

Conclusion

Advertisement

 

Oligodynamic silver hydrosol is the most promising and safe global

pathogen solution of this era.

 

Correspondence

 

The two authors have extensive clinical experience using picoscalar

oligodynamic silver hydrosol. Neither author has any financial ties to

commercial or proprietary silver hydrosol products. Eric Gordon, MD,

is Medical Director for Gordon Medical Associates in Santa Rosa,

California. He may be contacted at gordonmd. Kent Holtorf is

Medical Director for the Hormone and Longevity Medical Center, Inc. at

23441 Madison Street, #215, Torrance, California 90505; 310-375-2705.

He may be reached at www.hormoneandlongevitycenter.com.

 

Correction

 

In Part I of " A Promising Cure for URTI Pandemics, Including H5N1 and

SARS, " a typographical error altered an important number. Under the

last section in the article, covering IV drips, an incorrect range was

provided for the amount of silver hydrosol administration. The correct

range is between 150cc and 1500cc, not 750cc and 1500cc, as

erroneously printed.

 

[iLLUSTRATION OMITTED]

 

References

 

1. See:

http://www.clevelandclinicmeded.com/diseasemanagement/infectiousdisease/urti/urt\

i.htm

 

2. See: http://www.dartmouth.edu/~health/resources/uri.html

 

3. United States Patents: 5,017,295; 5,073,382; 5,078,902; 5,089,275;

5,098,582; 5,211,855; 5,223,149; 5,336,416; 5,336,499; 5,772,896.

 

4. Antelman, M. Multivalent silver bacteriocides. Precious Metals.

1992;16:151-63.

 

5. Antelman, M. Anti-pathogenic multivalent silver molecular

semiconductors. Precious Metals. 1992;16:141-9.

 

6. Dean, W, et al. Reduction of viral load in aids patients with

intravenous mild silver protein--three case reports. Clinical Practice

of Alternative Medicine. Spring, 2001.

 

7 Oka, H, et al. Inactivation of enveloped viruses by a

silver-thiosulfate complex. Metal Based Drugs. 1994;1(5-6):511.

 

8. Antelman, M. Silver. (II, III) Disinfectants.

Soap/Cosmetics/Chemical Specialties. March, 1994; p. 52-9.

 

9. Hussain, S, et al. Cystine protects na, k-atpase and isolated human

lymphocytes from silver toxicity. Biochem Biophys. Res. Comm.

1992;189:1444-1449.

 

10. Aiken, C, Dec 16, 1997; In vitro MIC Test Against HIV-1, published

account via email, AA-90 Results. Vanderbilt University, School of

Medicine.

Advertisement

 

11. Zhong-Yin, Z, et al. Zinc inhibition of renin and the protease

from human immunodeficiency virus type 1. Biochemistry. 1991;Sept 10;

30(36):8717-21.

 

12. Grier, N. Silver and its compounds. In: Disinfection,

Sterilization and Preservation, S. Block, ed. Philadelphia, PA: Lea &

Febiger;1983; p. 380.

 

13. Shimizu, F, Shimizu, Y, Kumagai, K. Specific inactivation of

herpes simplex virus by silver nitrate at low concentrations and

biological activities of the inactivated virus. Antimicrobial Agents

and Chemotherapy. July 1976;10(1):57-63.

 

14. Thurman, RB, CP Gerba. The molecular mechanisms of copper and

silver ion disinfection of bacteria and viruses. CRC Critical Reviews

in Environmental Control. 1989; 301.

 

15. Coleman, VR, J Wilkie, WE Levinson, T Stevens, E Javetz,

Inactivation of herpesvirus hominis types 1 and 2 by silver nitrate in

vitro and in vivo. Antimicrob. Agents & Chemother. 1973; 4:259.

 

16. Russell, AD, Hugo, WB. Antimicrobial activity and action of

silver. Prog Med Chem. 1994; 31:354.

 

17. Chang, TW, Weinstein., L. In vitro activity of silver sulfadiazine

against herpesvirus hominis. J Infect Dis. July 1975; 132(1):79-81.

 

18. Tokumaru, T, Shimizu, Y, Fox, CL. Antiviral activities of silver

sulfadiazine in ocular infection. Res Commun Chem Pathol Pharmacol.

May 1974; 8:151-8.

 

19. Searle, AB. The use of colloids in health and disease. (Quoting

from the British Medical Journal. Jan. 15, 1919; Is(17):83.

 

20. Thurman, RB, CP Gerba. The molecular mechanisms of copper and

silver ion disinfection of bacteria and viruses. CRC Critical Reviews

in Environmental Control. 1989; 301.

 

21. Cliver, DO, Sarles, WB, Foell, WK, Goepfert, JM. Biocidal Effects

of Silver: Contract NAS 9-9300 Final Technical Report. University of

Wisconsin, Accession Number--N70 23888, NASA CR Number--CR-108338,

February 1970; p. 4-4 through 4-6.

 

22. Searle, A B. " The Use of Colloids in Health and Disease. " (Quoting

J. MacMunn in the British Medical Journal, 1917, I, 685). New York: E.

P. Dutton and Company; 1919; p. 86.

 

23. Mahnel, H, M Schmidt. Effect of silver compounds on viruses in

water. Zentralbl. Baktenol. Parasitenk. Infektionskr. Hyg. Abt. Orig.

Reihe B. 1986; 182:381.

 

24. " Septacrol. " Merck's Index, fourth edition. Rahway, NJ: Merck &

Co., Inc.;1930; p. 456.

Advertisement

 

25. Thurman, RB, CP Gerba. The molecular mechanisms of copper and

silver ion disinfection of bacteria and viruses. CRC Critical Reviews

in Environmental Control. 1989; 301.

 

26. Cliver, DO, Sarles, WB, Foell, WK, Goepfert, JM. Biocidal Effects

of Silver: Contract NAS 9-9300 Final Technical Report. University of

Wisconsin, Accession Number--N70 23888, NASA CR Number--CR-108338,

February 1970; p. 4-2 through 4-4.

 

27. Brigham Young University, Microbiology Department, May 13th, 1999;

Ron W. Leavitt, PhD, Prof. Microbiology; ref: ASAP--1.25 ppm to 10 ppm

concentrate of Ag+.

 

28. Cliver, DO, Sarles, WB, Foell, WK, Goepfert, JM. Biocidal Effects

of Silver: Contract NAS 9-9300 Final Technical Report, University of

Wisconsin. Accession Number--N70 23888. NASA CR Number--CR-108338.

February 1970; p. 4-4 through 4-6.

 

29. Moyers. CA. et al. Treatment of large human burns with 0.5% silver

nitrate solution. Arch Surg. June 1965; 90:825.

 

30. Larry C. Ford, MD, Department of Obstetrics and Gynecology, UCLA

School of Medicine, Center for the Health Sciences, November 1, 1988.

 

31. Grier, N. " Silver and Its Compounds. " In: Disinfection,

Sterilization and Preservation, S. Block, ed. Philadelphia, PA:Lea &

Febiger;1983; p. 379.

 

32. Carr, HS, Wlodkowski, TJ, Rosenkranz, HS. Silver sulfadiazine: in

vitro antibacterial activity. Antimicrobial Agents and Chemotherapy.

Nov 1973; 4(5):585-6.

 

33. Hamilton-Miller. Shah, S, Shah, C. Silver sulphadiazine: a

comprehensive in vitro reassessment. Chemotherapy. 1993; 39:406.

 

34. Searle, A B. " The Use of Colloids in Health and Disease. "

(quoting Sir James Cantlie in the British Medical Journal, Nov. 15,

1913). New York: E.P. Dutton and Company; 1919; p. 83.

 

35. Searle, A B. " The Use of Colloids in Health and Disease. " (quoting

C.E.A. MacLeod in Lancet, Feb. 3, 1912). New York: E.P. Dutton and

Company, 1919; p. 83.

 

36. " Neo-Protosil, " Merck's Index, fourth edition. Rahway, NJ:Merck &

Co., Inc.; 1930; p. 350.

 

37. " Silver Floride, Silver Iodate, Silver Iodide, Silver Lactate,

Silver Nitrate " Merck's Index, fourth edition. Rahway, NJ:Merck & Co.,

Inc.;1930; p. 460.

 

38. " Neo-Protosil, " Merck's Index, fourth edition. Rahway, NJ:Merck &

Co., Inc.;1930; p. 350.

 

39. Searle, A B. The Use of Colloids in Health and Disease. (quoting

C.E.A. MacLeod in Lancet, Feb. 3, 1912). New York:E.P. Dutton and

Company;1919; p. 83.

Advertisement

 

40. Searle, A B. " The Use of Colloids in Health and Disease. " (quoting

J. Mark Hovell in the British Medical Journal, Dec. 15, 1917), E. P.

Dutton and Co.; 1919; p. 86.

 

41. " Collargol, " Merck's Index, fourth edition, Merck & Co., Inc.,

Rahway, NJ, 1930; p. 178.

 

42. Searle, A B, " The Use of Colloids in Health and Disease. " (Quoting

C.E. A. MacLeod in Lancet, Feb. 3, 1912). New York:E. P. Dutton and

Company;1919; p. 83.

 

43. " Silver Floride, Silver Iodate, Silver Iodide, Silver Lactate,

Silver Nitrate " Merck's Index, fourth edition. Rahway, NJ:Merck & Co.,

Inc.;1930; p. 460.

 

44. See: http://www.emedicine.com/med/topic2184.htm

 

45. Searle, A B. " The Use of Colloids in Health and Disease, " (quoting

from the British Medical Journal, Jan. 15, I(s)17). New York:E. P.

Dutton and Co.;1919; p. 83.

 

46. " Argenol, " Merck's Index, fourth edition. Rahway, NJ:Merck & Co.,

Inc.;,1930; p. 91.

 

47. See:

http://www.clevelandclinicmeded.com/diseasemanagement/infectiousdisease/urti/urt\

i.htm#definition

 

48. " Collargol, " Merck's Index, fourth edition. Rahway, NJ:Merck &

Co., Inc.:,1930; p. 178.

 

49. Brigham Young University, Microbiology Department, May 13th, 1999;

Ron W. Leavitt, PhD, Prof. Microbiology; ref: ASAP--1.25 ppm to 10 ppm

concentrate of Ag+.

 

50. Bechhold, H, Colloids in Biology and Medicine, translated by J. G.

M. Bullow,D. New York:Van Nostrand Company;1919; p. 376.

 

51. Grier, N, " Silver and Its Compounds. " In: Disinfection,

Sterilization and Preservation, S. Block, ed. Philadelphia, PA:Lea &

Febiger;1983; p. 380.

 

52. " Collargol, " Merck's Index, fourth edition. Rahway, NJ: Merck &

Co., Inc.;1930; p. 178.

 

53. Carr, HS, Wlodkowski, TJ, Rosenkranz, HS. Silver sulfadiazine: in

vitro antibacterial activity. Antimicrobial Agents and Chemotherapy

Nov 1973; 4(5):585-6.

 

54. Larry C. Ford, MD, Department of Obstetrics and Gynecology, UCLA

School of Medicine, Center for the Health Sciences, November 1, 1988.

 

55. Searle, A B, The Use of Colloids in Health and Disease, (quoting

C.E. A. MacLeod in Lancet, Feb. 3, 1912). New York:E. P. Dutton and

Company;1919; p. 83.

 

56. Searle, A B, The Use of Colloids in Health and Disease, (quoting

Henry Crookes). New York:E. P. Dutton and Company;1919; p. 70.

Advertisement

 

57. " Collargol, " Merck's Index, fourth edition. Rahway, NJ:Merck &

Co., Inc.; 1930; p. 178.

 

58. " Proganol, " Merck's Index, fourth edition. Rahway, NJ:Merck & Co.,

Inc.;1930; p. 422.

 

59. " Protargol, " Merck's Index, fourth edition. Rahway, NJ:Merck &

Co., Inc.;1930; p. 424.

 

60. " Silver Nitrite, Silver Nucleinate, Silver Oxalate, Silver Oxide,

Silver Permanganate, Silver Phenolsulphonate " Merck's Index, fourth

edition. Rahway, NJ:Merck & Co., Inc.:1930; p. 461.

 

61. Grier, N, " Silver and Its Compounds. " In: Disinfection,

Sterilization and Preservation, S. Block, ed. Philadelphia, PA:Lea &

Febiger;1983; p. 380.

 

62. Shimizu, F, Shimizu, Y, Kumagai, K. Specific inactivation of

herpes simplex virus by silver nitrate at low concentrations and

biological activities of the inactivated virus. Antimicrobial Agents

and Chemotherapy. July 1976; 10(1):57-63.

 

63. Thurman, RB, CP Gerba. The molecular mechanisms of copper and

silver ion disinfection of bacteria and viruses. CRC Critical Reviews

in Environmental Control, 1989; 301.

 

64. Coleman, VR, J Wilkie, WE Levinson, T Stevens, E Javetz.

Inactivation of herpesvirus hominis types 1 and 2 by silver nitrate in

Vitro and in Vivo. Antimicrob. Agents & Chemother. 1973; 4:259.

 

65. Russell, AD, Hugo, WB. Antimicrobial activity and action of

silver. Prog Med Chem, 1994; 31:354.

 

66. Chang, TW, Weinstein, L. In vitro activity of silver sulfadiazine

against herpesvirus hominis, " J Infect Dis. July 1975; 132(1):79-81.

 

67. Oka, H, et al., " Inactivation of Enveloped Viruses by a

Silver-Thiosulfate Complex, " Metal-Based Drugs, edited by Frank Shaw,

III, 1994; 1(5-6):511.

 

68. Tokumaru, T, Shimizu, Y, Fox, CL. Antiviral activities of silver

sulfadiazine in ocular infection. Res Commun Chem Pathol Pharmacol,

May 1974; 8(1):151-8.

 

69. Johns Hopkins University, Department of Pathology, Division of

Microbiology, Feb 14th, 1997, James D. Dick, PhD, Director of

Bacteriology; Ref: Aqua Argentica.

 

70. Hamilton-Miller, Shah, S, Shah, C, Silver sulphadiazine: a

comprehensive in vitro reassessment. Chemotherapy. 1993; 39:406.

 

71. Brigham Young University, Microbiology Department, May 13th, 1999;

Ron W. Leavitt, PhD, Prof. Microbiology; ref: ASAP--1.25 ppm to 10 ppm

concentrate of Ag+.

 

72. Brigham Young University, Microbiology Department, May 13th, 1999;

Ron W. Leavitt, PhD, Prof. Microbiology; ref: ASAP--1.25 ppm to 10 ppm

concentrate of Ag+.

Advertisement

 

73. Searle, A B, The Use of Colloids in Health and Disease, (Quoting

J. Mark Hovell in the British Medical Journal, Dec. 15, 1917). New

York:E. P. Dutton and Company;1919; p. 86.

 

74. " Silver Floride, Silver Iodate, Silver Iodide, Silver Lactate,

Silver Nitrate " Merck's Index, fourth edition. Rahway, NJ:Merck & Co.,

Inc.;1930; p. 460.

 

75. " Neo-Protosil, " Merck's Index, fourth edition. Rahway, NJ:Merck &

Co., Inc.;1930; p. 350.

 

76. " Neo-Silvol, " Merck's Index, fourth edition. Rahway, NJ:Merck &

Co., Inc.;1930; p. 350.

 

77. " Proganol, " Merck's Index, fourth edition. Rahway, NJ:Merck & Co.,

Inc.;1930; p. 422.

 

78. " Protargol, " Merck's Index, fourth edition. Rahway, NJ:Merck &

Co., Inc.;1930; p. 424.

 

79. " Silver Floride, Silver Iodate, Silver Iodide, Silver Lactate,

Silver Nitrate " Merck's Index, fourth edition. Rahway, NJ:Merck & Co.,

Inc.;1930; p. 460.

 

80. " Silver Protein, Silver Calculate, Silver Sulphate, Silver

Sulphide, Silver & Potassium Cyanide, Silver & Sodium Chloride, Silver

& Sodium Thiosulphate, Silver & Thallium Nitrate, Silvol " Merck's

Index, fourth edition. Rahway, NJ:Merck & Co., Inc.;1930; p. 462.

 

81. Searle, A B, The Use of Colloids in Health and Disease, (Quoting

C.E. A. MacLeod in Lancet, Feb. 3, 1912). New York:E.P. Dutton and

Company;1919; p. 83.

 

82. Bechhold, H, Colloids in Biology and Medicine, translated by J. G.

M. Bullow. D. New York:Van Nostrand Company; 1919; p. 368.

 

83. " Septacrol, " Merck's Index, fourth edition, Merck & Co., Inc.,

Rahway, NJ, 1930; p. 456.

 

84. Antelman; Marvin S. " Method of curing AIDS with tetrasilver

tetroxide molecular crystal devices, " USPTO #5,676,977, October 14, 1997

 

85. See: EPA/IRIS CASRN 7440-22-4, 1996. The EPA has provided dosage

ranges that indicate not to: (1) exceed 1 gram of silver IV exposure

over a 2 to 9 year time period for an average adult weighing 70 kg, or

(2) not to exceed 25 grams orally over a lifetime for an average adult

weighing 70 kg.

 

86. CRC Handbook of Chemistry and Physics, 80th Edition, ed. by David

R. Lide. Boca Ratan, FL:CRC Press. 1999-2000, Section 15.

 

87. Agency for Toxic Substances and Disease Registry (ATSDR)

Toxicological Profile for Silver--CAS# 7440-22-4, Dec. 1990, Section:

2.3.2.4--OTHER ROUTES OF EXPOSURE.

 

88. Fung, MC, DL Bowen. Silver products for medical indication:

risk-benefit assessment. Clinical Toxicology. 1996; 34(1):121.

Advertisement

 

89. Rungby, J, G Danscher. Localization of exogenous silver in brain

and spinal cord of silver exposed rats. Acta Pharmacol Toxicol. 1984;

60:92-8.

 

90. Duhamel, BG. Electric metallic colloids and their therapeutic

applications. Lancet Jan. 13, 1912.

 

91. Fuller, AW. Severe epidemic encephalitis. Lancet. July 24, 1926;

2: 172. Also see JAMA. Sept. 25, 1926; p. 1071.

 

92. Thurman, RB, CP Gerba, " The Molecular Mechanisms of Copper and

Silver ion Disinfection of Bacteria and Viruses. " A paper presented in

the First International Conference on Gold and Silver in Medicine, The

Silver Institute, Washington, DC, 1989; 18(4):301.

 

93. Gallyas, F. Physico-hemical mechanism of the argyrophil I

reaction. Histochemistry. 1982; 74:393.

 

94. Gallyas, F. Simultaneous determination of the amounts of metallic

and reducible silver in histologic specimens. Histochemistry 1979;

64:77-86.

 

95. Padlewska, KK, RA Schwartz. eMedicine Journal. Nov. 2, 2001;

2(11):(see under Histologic Findngs). www.emedicine.com/derm/topic595.htm

 

96. Jansson, G, M Harms-Ringdahl. Stimulating effects of mercuric- and

silver ions on the superoxide anion in human polymorphonuclear

leukocytes. Free Radic Res Commun. 1993; 18(2):87-98.

 

97. Clayton, GD, FE Clayton. Patty's Industrial Hygiene and

Toxicology, 3rd revised edition. New York:John Wiley & Sons; 1981;

1881-94.

 

98. Fowler, BA, GF Nordberg, " Silver, " In: Handbook on the Toxicology

of Metals, 1st edition., Friberg, L., Norbderg, GF, VB Vouk, eds. New

York: Elsevier/North-Holland Biomedical Press; 1979; 579-86.

 

99. Clayton, GD, FE Clayton. Patty's Industrial Hygiene and

Toxicology, 3rd revised edition. New York:John Wiley & Sons;1981; p.

1881-94.

 

100. Fowler, BA, GF Nordberg. " Silver, " In: Handbook on the Toxicology

of Metals, 1st edition, Friberg, L., Norbderg, GF, Vouk, VB, eds. New

York: Elsevier/North-Holland Biomedical Press;1979; p. 579-86.

 

101. Samuni, A, et al. On the cytotoxicity of vitamin c and metal

ions. Eur J Biochem. 1983; 99:562.

 

102. Jansson, G, Harms-Ringdahl, M. Stimulating effects of mercuris-

and silver ions on the superoxide anion production in human

polymorphonuclear leukocytes. Free Radic Res commun. 1993; 18(2):87-98.

 

103. Horsmanheimo, M. Lack of proliferation of circulating white blood

cells in patients with syphilis before and after a jarisch-herxheimer

reaction. Br J Vener Dis Aug 1978; 54:225-8.

Advertisement

 

104. Loveday, C, JS Bingham. Changes in circulating immune complexes

during the jarisch herxheimer reaction in secondary syphilis. Eur J

Clin Microbiol Infect Dis Mar 1993; 12:185-91.

 

105. Jansson, G, Harms-Ringdahl, M. Stimulation effects of mercuric-

and silver ions on the superoxide anion production in human

polymorphonuclear leukocytes. Free Radic Res Commun. 1993; 18(2):87-98.

 

106. Brown, G. Colloidal silver in sepsis. Journal of the American

Association of Obstetricians and Gynecologists. Jan, 1916.

 

107. Bechhold, H, Bullowa, JGM. Colloids in Biology and Medicine. New

York:D. Van Nostrand Co.;1919; p. 371-4.

 

108. Brown, G. " Colloidal silver in sepsis. Journal of the American

Association of Obstetricians and Gynecologists. Jan, 1916.

 

109. Dean, W, et al.. Reduction of viral load in aids patients with

intravenous mild silver protein--three case reports. Clinical Practice

of Alternative Medicine Spring, 2001.

 

110. Bechhold, H, Bullowa, JGM. Colloids in Biology and Medicine. New

York: D. Van Nostrand Co.;1919; p. 371-2.

 

111. Rikimaru, T, et al. Three cases of localized pleural tuberculosis

which looked exacerbated during antituberculous chemotherapy. Kekkaku

Feb 1991; 66:101-7.

 

112. Karachunskii, MA. Exacerbation of pulmonary tuberculosis during

chemotherapy Probl Tuberk. 1996; p. 23-5.

 

113. Lawrence, C, et al. Seronegative chronic relapsing

neuroborreliosis. Eur Neurol. 1995; 35:113-7.

 

114. Feng, QL, et al. A mechanistic study of the antibacterial effect

of silver ions on escherichia coli and staphylococcus aureus. J Biomed

Mater Res. March 2000; 52:662.

 

115. Antelman; Marvin S. Method of curing AIDS with tetrasilver

tetroxide molecular crystal devices. USPTO # 5,676,977, October 14, 1997

 

116. Antelman; Marvin S. Method of curing AIDS with tetrasilver

tetroxide molecular crystal devices. USPTO # 5,676,977, October 14, 1997

 

117. Eichorn, GL, et al. " Interaction of metal ions with biological

systems, with special reference to silver and gold. Proceedings of the

First International Conference on Gold and Silver In Medicine,

Bethesda, MD, May 13-14, published by The Silver Institute,

Washington, D.C., 1987; p. 4.

 

118. Bodansky, M. Introduction to Physiological Chemistry. New York:

John Wiley & Sons, Inc.;1934; p. 22-3.

Advertisement

 

119. Bechhold, H. Colloids in Biology and Medicine, translated by

Bullowa, JGM. New York:D. Van Nostrand Co.;1919; p. 13, 366 & 368.

 

120. Hartman, RJ. Colloid Chemistry. Cambridge, MA: Houghton Mifflin

Co., The Riverside Press;1939; p. 13.

 

121. Cliver, DO, et al. Biocidal Effects of Silver: Contract NAS

9-9300 Final Technical Report. University of Wisconsin, Accession No.

N71-24436, NASA CR-114978, Code G3, Category 04, February 1971; p. 5-2.

 

122. EPA/IRIS CASRN 7440-22-4, 1996.

 

123. Agency for Toxic Substances and Disease Registry (ATSDR)

Toxicological Profile for Silver--CAS# 7440-22-4, Dec. 1990.

 

124. Zhao, G, SE Stevens. Multiple parameters for the comprehensive

evaluation of the susceptibility of escherichia coli to the silver

ion. Bio Metals. 1998; 11:28.

 

125. Cliver, DO, et al., " Biocidal Effects of Silver: Contract NAS

9-9300 Final Technical Report, " University of Wisconsin, Accession No.

N71-24436, NASA CR-114978, Code G3, Category 04, February 1971; p. 3-1.

 

126. Simonetti, N, Simonetti, G, Bougonl, F, Scalzo, M.

Electrochemical Ag+ for preservative use. Applied and Environmental

Microbiology. Dec 1992; 58(12):3834.

 

127. Baker C, et al. Synthesis and antibacterial properties of silver

nanoparticles. 2005 Feb;5(2):244-9.

 

128. Woods, HC, et al. The Dispensatory of The United States of

America, Centennial (22nd) Edition. Philadelphia, PA: J.B. Lippincott

Co.;1937; p. 1578.

 

129. (E. Fougera & Co.) Reports Council on Pharmacy and Chemistry

Reports, 1920; p. 58.

 

130. Council on Pharmacy and Chemistry of the American Medical

Association, In: Hill, WR, Pillsbury, DM. Argyria: The Pharmacology of

Silver. Baltimore, MD:The Williams & Wilkins Co.;1939; p. 170.

 

131. Woods, HC, et al. The Dispensatory of The United States of

America, Centennial (22nd) Edition. Philadelphia, PA:J.B. Lippincott

Co.;1937; p. 1578.

 

132. Searle, A B. The Use of Colloids in Health and Disease. (Quoting

J. MacMunn in the British Medical Journal, 1917, I, 685). New York: E.

P. Dutton and Company;1919; p. 86.

 

133. Duhamel, BG. Electric metallic colloids and their therapeutic

applications. Lancet. Jan. 13, 1912.

 

134. The study used 40 ppm concentrations of tetrasilver tetroxide. By

deducting the oxygen amount, this leaves the equivalent of 27 ppm pure

silver concentration.

 

135. Antelman; Marvin S. Method of curing AIDS with tetrasilver

tetroxide molecular crystal devices. USPTO # 5,676,977, October 14, 1997

Advertisement

 

136. Fung, M.C., Bowen, D.L. Silver products for medical indications:

risk-benefit assessment. Clinical Toxicology. 34(1), 119-126, 1996.

 

137. Phamax: Nutriceutical & Biophysical Systems, product catalogue,

WA, page PA 03. See www.pharmaxllc.com.

 

138. Yakovlev AI, Zvyagin SG. Influence of phytoncides on virus

influenza A. Action of the volatile components from garlic and onion

on virus influenza A. Byull Biol Med (Bull Biol Med). 29:384-387, 1950

(Russian).

 

139. Cai Y. Anticryptococcal and antiviral properties of garlic.

Cardiol Pract, 9:11, 1991.

 

140. Tsai Y, Cole LL, Davis LE, Lockwood SJ, Simmons V, Wild GC.

Antiviral properties of garlic: in vitro effects on influenza B,

herpes simplex, and coxsackie viruses. Planta Med 51:460-461, 1985.

 

141. Phamax: Nutriceutical & Biophysical Systems, product catalogue,

WA, page PB 12. See www.pharmaxllc.com.

 

142. De Whalley, CV, et al. Biochem Pharmacology. 1990; 39:1743-50.

 

143. Renis, HE. In-vitro antiviral activity of calcium elenolate.

Antimocrobial Agents and Chemotherapy. 1969; 167-72.

 

144. Renis, HE. Inactivation of myxoviruses by calcium elenolate.

Antimicrobial Agents and Chemotherapy. August 1975; 194-9.

 

145. Renis, HE. Influenza virus infection of hamsters. A model for

evaluating antiviral drugs. Archives of Virology. 1977; 54:85-93.

 

by Eric Gordon, MD and Kent Holtorf, MD

 

[c]2006. All rights reserved.

 

COPYRIGHT 2006 The Townsend Letter Group

COPYRIGHT 2006 Gale Group